STUDY | ADMIN | CCADMIN | ACCR. GOAL |
R E G |
O P E N |
ARM | TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | PEOLC | 491 | 1 | Y | 0 Screening | 386 | 57 | 51 | 20 | 7 | 1 | 11/01/2017 | 240 | 85 | |
386 | 57 | 51 | 20 | 7 | 1 | ||||||||||
2 | Y | 1 Carvedilol | 74 | 0 | 0 | 0 | 0 | 0 | |||||||
2 No prophylaxis | 81 | 0 | 0 | 0 | 0 | 0 | |||||||||
3 Observation | 194 | 39 | 36 | 17 | 6 | 2 | |||||||||
349 | 39 | 36 | 17 | 6 | 2 | ||||||||||
S1703-Met Breast, STM-monitoring v Usual Care | CCD | SXQOL | 739 | 1 | Y | 0 Screening | 614 | 105 | 56 | 26 | 7 | 1 | 09/17/2018 | 229 | 93 |
614 | 105 | 56 | 26 | 7 | 1 | ||||||||||
2 | Y | 1 Control (Usual Care) | 204 | 33 | 17 | 7 | 2 | 0 | |||||||
2 Intervention (STMDDM) | 208 | 35 | 19 | 9 | 3 | 0 | |||||||||
412 | 68 | 36 | 16 | 5 | 0 | ||||||||||
S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | GU | SXQOL | 1273 | 1 | Y | 0 Induction SST | 935 | 117 | 64 | 34 | 16 | 4 | 09/24/2018 | 329 | 138 |
935 | 117 | 64 | 34 | 16 | 4 | ||||||||||
2 | Y | 1 Standard Systemic Therapy Only | 337 | 50 | 21 | 14 | 4 | 0 | |||||||
2 SST + Surgery/RT | 330 | 41 | 15 | 9 | 3 | 0 | |||||||||
667 | 91 | 36 | 23 | 7 | 0 | ||||||||||
S1803-MM, Maintenance, Len vs Len/Dara | MMYEL | SXQOL | 1100 | 2 | Y | 1 Lenalidomide | 674 | 86 | 21 | 4 | 0 | 0 | 08/13/2019 | 29 | 5 |
2 Lenalidomide + Daratumumab | 664 | 83 | 22 | 4 | 2 | 1 | |||||||||
1338 | 169 | 43 | 8 | 2 | 1 | ||||||||||
3 | Y | 3 Continue Lenalidomide | 40 | 13 | 7 | 4 | 0 | 0 | |||||||
4 Stop Lenalidomide | 42 | 13 | 7 | 3 | 0 | 0 | |||||||||
5 Continue Lenalidomide + Dara | 95 | 28 | 15 | 5 | 1 | 0 | |||||||||
6 Stop Lenalidomide + Dara | 97 | 30 | 18 | 5 | 1 | 1 | |||||||||
274 | 84 | 47 | 17 | 2 | 1 | ||||||||||
S1827-SCLC, MRI Surveillance +/- PCI | LUNG | SXQOL | 668 | 1 | Y | 1 PCI + MRI brain surveillance | 142 | 29 | 16 | 5 | 1 | 0 | 05/04/2020 | 344 | 128 |
2 MRI brain surveillance | 143 | 29 | 18 | 10 | 2 | 0 | |||||||||
285 | 58 | 34 | 15 | 3 | 0 | ||||||||||
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | LYMPH | SXQOL | 422 | 1 | T | 1 CC-486 + R-miniCHOP | 69 | 16 | 5 | 0 | 0 | 0 | 05/25/2021 | 178 | 65 |
2 R-miniCHOP | 67 | 13 | 6 | 0 | 0 | 0 | |||||||||
136 | 29 | 11 | 0 | 0 | 0 | ||||||||||
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | LEUK | SXQOL | 247 | 1 | Y | 1 Delayed V-O | 52 | 14 | 7 | 3 | 0 | 0 | 03/02/2021 | 284 | 102 |
2 Early V-O | 101 | 31 | 18 | 11 | 3 | 1 | |||||||||
153 | 45 | 25 | 14 | 3 | 1 | ||||||||||
S2013-I-CHECKIT: ICI toxicity risk prediction study | SXQOL | 3609 | 1 | Y | 1 Observation Arm | 2233 | 149 | 134 | 66 | 18 | 2 | 09/13/2021 | 230 | 116 | |
2233 | 149 | 134 | 66 | 18 | 2 | ||||||||||
S2205-ICE COMPRESS: Reduction of CIPN from Taxanes | SXQOL | 777 | 1 | Y | 1 Cryocompression | 132 | 75 | 39 | 21 | 9 | 1 | 06/06/2023 | 16 | 30 | |
2 Continuous Compression | 129 | 74 | 40 | 22 | 8 | 0 | |||||||||
3 Low Cyclic Compression | 129 | 72 | 35 | 18 | 6 | 3 | |||||||||
390 | 221 | 114 | 61 | 23 | 4 | ||||||||||
S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | BREAST | SXQOL | 960 | 1 | Y | 1 Tissue for MammaPrint testing | 584 | 478 | 282 | 143 | 46 | 10 | 11/27/2023 | 376 | 133 |
584 | 478 | 282 | 143 | 46 | 10 | ||||||||||
2 | Y | 2 SOC Chemotherapy | 99 | 84 | 51 | 26 | 8 | 3 | |||||||
3 SOC Chemotherapy + Durvalumab | 98 | 84 | 52 | 29 | 11 | 2 | |||||||||
197 | 168 | 103 | 55 | 19 | 5 | ||||||||||
S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | LYMPH | SXQOL | 227 | 1 | Y | 1 Tazemetostat (Arm 1) Dose Level 1 | 7 | 0 | 0 | 0 | 0 | 0 | 09/26/2023 | 120 | 34 |
4 Zanubrutinib (Arm 3) Dose Level 1 | 10 | 0 | 0 | 0 | 0 | 0 | |||||||||
5 Zanubrutinib (Arm 3) Dose Level 2 | 10 | 10 | 0 | 0 | 0 | 0 | |||||||||
27 | 10 | 0 | 0 | 0 | 0 | ||||||||||
S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | MMYEL | SXQOL | 510 | 1 | Y | 1 VRD-R | 29 | 19 | 9 | 4 | 1 | 0 | 10/12/2023 | 259 | 82 |
2 DRD-R | 30 | 20 | 10 | 5 | 3 | 1 | |||||||||
3 DRD-DR | 26 | 17 | 8 | 4 | 1 | 0 | |||||||||
85 | 56 | 27 | 13 | 5 | 1 | ||||||||||
S2212-Breast, TNBC, Neoadj Chemo + Pembro | BREAST | SXQOL | 2400 | 1 | Y | 1 Carbo + Paclitaxel + Pembro -> AC + Pembro | 364 | 267 | 148 | 81 | 34 | 7 | 09/15/2023 | 380 | 147 |
2 Carbo + Docetaxel + Pembro | 369 | 270 | 151 | 81 | 34 | 8 | |||||||||
733 | 537 | 299 | 162 | 68 | 15 | ||||||||||
S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | MMYEL | SXQOL | 338 | 1 | Y | 0 Induction | 14 | 13 | 7 | 3 | 0 | 0 | 07/01/2024 | 145 | 43 |
14 | 13 | 7 | 3 | 0 | 0 | ||||||||||
2 | Y | 1 Dara-VCD | 4 | 4 | 3 | 2 | 1 | 0 | |||||||
2 Melphalan + ASCT | 4 | 4 | 3 | 2 | 1 | 0 | |||||||||
8 | 8 | 6 | 4 | 2 | 0 | ||||||||||
3 | Y | 3 Dara | 1 | 1 | 1 | 0 | 0 | 0 | |||||||
1 | 1 | 1 | 0 | 0 | 0 | ||||||||||
S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo | GI | SXQOL | 224 | 1 | Y | 1 Nivolumab + Paclitaxel + Ramucirumab | 20 | 20 | 14 | 9 | 1 | 0 | 06/24/2024 | 257 | 90 |
2 Paclitaxel + Ramucirumab | 22 | 21 | 15 | 12 | 5 | 1 | |||||||||
42 | 41 | 29 | 21 | 6 | 1 | ||||||||||
S2408-Panc Fistula Prevention, Lanreotide | PEOLC | 274 | 1 | Y | 1 Blinded Drug | 4 | 4 | 4 | 4 | 0 | 0 | 05/09/2025 | 62 | 24 | |
2 Blinded Drug | 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
5 | 5 | 5 | 5 | 0 | 0 | ||||||||||
S2414-NSCLC, Stg II-IIIB, Durva vs Surveillance | LUNG | SXQOL | 306 | 1 | Y | 1 Durvalumab | 2 | 2 | 2 | 1 | 0 | 0 | 04/01/2025 | 225 | 45 |
2 | 2 | 2 | 1 | 0 | 0 | ||||||||||
A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib | BREAST | SXQOL | 1 | E | 55 | 11 | 4 | 1 | 0 | 0 | 03/11/2021 | 438 | 206 | ||
55 | 11 | 4 | 1 | 0 | 0 | ||||||||||
A012103-Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab | BREAST | SXQOL | 1 | E | 33 | 25 | 18 | 12 | 4 | 0 | 08/24/2023 | 375 | 185 | ||
33 | 25 | 18 | 12 | 4 | 0 | ||||||||||
A021806-Pancreas, Perioperative vs Adjuvant Chemo | GI | SXQOL | 0 | E | 41 | 5 | 4 | 1 | 0 | 0 | 10/08/2020 | 273 | 115 | ||
41 | 5 | 4 | 1 | 0 | 0 | ||||||||||
1 | E | 33 | 3 | 2 | 0 | 0 | 0 | ||||||||
33 | 3 | 2 | 0 | 0 | 0 | ||||||||||
A032103-Urothelial, All Stg, MRD-Based Adj Tx | GU | SXQOL | 0 | E | 30 | 28 | 22 | 7 | 3 | 0 | 03/19/2024 | 345 | 140 | ||
30 | 28 | 22 | 7 | 3 | 0 | ||||||||||
1 | E | 21 | 20 | 18 | 10 | 2 | 0 | ||||||||
21 | 20 | 18 | 10 | 2 | 0 | ||||||||||
2 | E | 2 | 2 | 2 | 2 | 0 | 0 | ||||||||
2 | 2 | 2 | 2 | 0 | 0 | ||||||||||
A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub | LYMPH | SXQOL | 1 | E | 19 | 14 | 5 | 2 | 1 | 0 | 01/03/2024 | 197 | 70 | ||
19 | 14 | 5 | 2 | 1 | 0 | ||||||||||
2 | E | 10 | 9 | 7 | 2 | 1 | 0 | ||||||||
10 | 9 | 7 | 2 | 1 | 0 | ||||||||||
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO | LUNG | SXQOL | 1 | E | 92 | 15 | 5 | 3 | 0 | 0 | 10/20/2020 | 422 | 173 | ||
92 | 15 | 5 | 3 | 0 | 0 | ||||||||||
A211901-Cancer survivors who smoke, txt cessation | SXQOL | 1 | E | 14 | 4 | 1 | 1 | 0 | 0 | 09/12/2023 | 137 | 51 | |||
14 | 4 | 1 | 1 | 0 | 0 | ||||||||||
ACCL16N1-Guideline Consistent Treatment AYA ALL | CCD | 1 | T | 54 | 0 | 0 | 0 | 0 | 0 | 10/24/2018 | |||||
54 | 0 | 0 | 0 | 0 | 0 | ||||||||||
AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy | LYMPH | SXQOL | 1 | E | 62 | 43 | 30 | 14 | 7 | 1 | 08/15/2023 | 272 | 128 | ||
62 | 43 | 30 | 14 | 7 | 1 | ||||||||||
2 | E | 48 | 34 | 23 | 16 | 3 | 2 | ||||||||
48 | 34 | 23 | 16 | 3 | 2 | ||||||||||
CCTGHN11-HN, All Stg, Guided Elec Contra Neck Tx | OTHER | SXQOL | 1 | E | 1 | 0 | 0 | 0 | 0 | 0 | 02/07/2024 | 81 | 20 | ||
1 | 0 | 0 | 0 | 0 | 0 | ||||||||||
2 | E | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
1 | 0 | 0 | 0 | 0 | 0 | ||||||||||
EA5221-Lung, Advanced NSCLC, ChemoImmuno/Immuno | LUNG | SXQOL | 1 | E | 3 | 3 | 2 | 1 | 0 | 0 | 08/07/2024 | 192 | 76 | ||
3 | 3 | 2 | 1 | 0 | 0 | ||||||||||
2 | E | 2 | 2 | 1 | 0 | 0 | 0 | ||||||||
2 | 2 | 1 | 0 | 0 | 0 | ||||||||||
EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | MMYEL | SXQOL | 0 | E | 56 | 10 | 6 | 3 | 2 | 0 | 05/27/2021 | 229 | 79 | ||
56 | 10 | 6 | 3 | 2 | 0 | ||||||||||
1 | E | 42 | 7 | 5 | 3 | 2 | 1 | ||||||||
42 | 7 | 5 | 3 | 2 | 1 | ||||||||||
2 | E | 30 | 9 | 2 | 1 | 1 | 0 | ||||||||
30 | 9 | 2 | 1 | 1 | 0 | ||||||||||
EAQ211-Lymph, Survivors, Health Disp. AYA | SURV | 1 | E | 4 | 4 | 3 | 1 | 1 | 0 | 12/24/2024 | |||||
4 | 4 | 3 | 1 | 1 | 0 | ||||||||||
EAQ222CD-CostCOM, Cancer Patients, OOP Cost Com | CCD | 0 | E | 24 | 24 | 18 | 9 | 3 | 0 | 08/27/2024 | 107 | 45 | |||
24 | 24 | 18 | 9 | 3 | 0 | ||||||||||
1 | E | 23 | 23 | 18 | 9 | 5 | 3 | ||||||||
23 | 23 | 18 | 9 | 5 | 3 | ||||||||||
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT | BREAST | SXQOL | 1 | E | 59 | 28 | 16 | 7 | 3 | 2 | 10/18/2019 | 406 | 154 | ||
59 | 28 | 16 | 7 | 3 | 2 | ||||||||||
2 | E | 57 | 27 | 15 | 7 | 3 | 2 | ||||||||
57 | 27 | 15 | 7 | 3 | 2 | ||||||||||
NRGCC010-Endo, Stg I, LN Map for LE Limb Dysfunction | SXQOL | OTHER | 1 | E | 15 | 5 | 2 | 2 | 1 | 0 | 12/07/2022 | 70 | 25 | ||
15 | 5 | 2 | 2 | 1 | 0 | ||||||||||
NRGCC011-Breast, Survivors, Cog Training | SXQOL | 0 | E | 50 | 47 | 14 | 4 | 0 | 0 | 04/03/2024 | 262 | 100 | |||
50 | 47 | 14 | 4 | 0 | 0 | ||||||||||
1 | E | 35 | 33 | 9 | 4 | 0 | 0 | ||||||||
35 | 33 | 9 | 4 | 0 | 0 | ||||||||||
NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide | GU | SXQOL | 1 | E | 14 | 1 | 0 | 0 | 0 | 0 | 09/25/2020 | 273 | 93 | ||
14 | 1 | 0 | 0 | 0 | 0 | ||||||||||
NRGGU011-Pros, Dbl Blinded RT +/- Androgen Dep Tx | GU | SXQOL | 1 | E | 18 | 9 | 6 | 2 | 1 | 0 | 03/29/2023 | 273 | 91 | ||
18 | 9 | 6 | 2 | 1 | 0 | ||||||||||
NRGLU008-Lung NSCL, StgII-III, StereoBodyRad/MedChemo | LUNG | SXQOL | 1 | E | 3 | 2 | 1 | 1 | 0 | 0 | 01/26/2024 | 306 | 121 | ||
3 | 2 | 1 | 1 | 0 | 0 | ||||||||||
A012301-Breast, Early Stg, Tamoxifen | BREAST | SXQOL | 1 | E | 7 | 7 | 7 | 6 | 3 | 1 | 03/07/2025 | 341 | 99 | ||
7 | 7 | 7 | 6 | 3 | 1 | ||||||||||
A031801-GU, mRCC, Cabozantinib ± Radium-223 | GU | SXQOL | 1 | E | 15 | 0 | 0 | 0 | 0 | 0 | 11/06/2020 | 109 | 39 | ||
15 | 0 | 0 | 0 | 0 | 0 | ||||||||||
A082002-Lung, Adv, Systemic Tx +/- SBRT | LUNG | SXQOL | 1 | E | 4 | 0 | 0 | 0 | 0 | 0 | 10/12/2022 | 244 | 70 | ||
4 | 0 | 0 | 0 | 0 | 0 | ||||||||||
A191901-Brst, Text/Motivational Intervention ET Adher | CCD | 1 | E | 42 | 3 | 1 | 0 | 0 | 0 | 06/14/2021 | 205 | 89 | |||
42 | 3 | 1 | 0 | 0 | 0 | ||||||||||
A212102-Blind Ref Set for Multicancer Early Detection | PREV | 1 | E | 217 | 104 | 43 | 18 | 3 | 0 | 11/28/2022 | 208 | 94 | |||
217 | 104 | 43 | 18 | 3 | 0 | ||||||||||
A222004-Mult, Olanza vs Megestrol for Anorexia | SXQOL | 1 | E | 7 | 2 | 0 | 0 | 0 | 0 | 03/17/2022 | 54 | ||||
7 | 2 | 0 | 0 | 0 | 0 | ||||||||||
A231602C-Blood Cancer, Assess Financial Difficulty | CCD | 1 | T | 4 | 0 | 0 | 0 | 0 | 0 | 06/04/2020 | |||||
4 | 0 | 0 | 0 | 0 | 0 | ||||||||||
ACCL1931-Leuk, All Stg, Levocarnitine Prophylaxis | SXQOL | 1 | E | 5 | 3 | 3 | 1 | 0 | 0 | 03/29/2024 | 153 | 70 | |||
5 | 3 | 3 | 1 | 0 | 0 | ||||||||||
2 | E | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||
0 | 0 | 0 | 0 | 0 | 0 | ||||||||||
AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | ERLYTX | SXQOL | 1 | E | 3 | 1 | 1 | 0 | 0 | 0 | 10/07/2021 | 191 | 120 | ||
3 | 1 | 1 | 0 | 0 | 0 | ||||||||||
2 | E | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||
0 | 0 | 0 | 0 | 0 | 0 | ||||||||||
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo | OTHER | SXQOL | 1 | T | 5 | 1 | 0 | 0 | 0 | 0 | 12/13/2019 | 180 | 92 | ||
5 | 1 | 0 | 0 | 0 | 0 | ||||||||||
CCTGCO32-Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad | GI | SXQOL | 1 | E | 7 | 6 | 4 | 4 | 2 | 0 | 06/26/2024 | 127 | 46 | ||
7 | 6 | 4 | 4 | 2 | 0 | ||||||||||
CCTGNE1-Midgut NET, Unresect, 177 Lut vs Ever | GI | SXQOL | 1 | E | 4 | 3 | 0 | 0 | 0 | 0 | 06/11/2024 | 64 | 18 | ||
4 | 3 | 0 | 0 | 0 | 0 | ||||||||||
CE7-Brain, 5+ Metastases, Radiosurg/Radiotherapy | OTHER | SXQOL | 1 | E | 1 | 0 | 0 | 0 | 0 | 0 | 06/17/2024 | 110 | 42 | ||
1 | 0 | 0 | 0 | 0 | 0 | ||||||||||
2 | E | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
1 | 0 | 0 | 0 | 0 | 0 | ||||||||||
EA2185-Panc, Impact of Panc Cyst Surveillance | PREV | SXQOL | 1 | E | 19 | 0 | 0 | 0 | 0 | 0 | 03/03/2021 | 128 | 73 | ||
19 | 0 | 0 | 0 | 0 | 0 | ||||||||||
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT | GU | SXQOL | 1 | E | 19 | 6 | 6 | 4 | 1 | 0 | 04/25/2019 | 42 | 16 | ||
19 | 6 | 6 | 4 | 1 | 0 | ||||||||||
2 | E | 1 | 1 | 1 | 1 | 0 | 0 | ||||||||
1 | 1 | 1 | 1 | 0 | 0 | ||||||||||
EA8191-Pros, Local vs Systemic Thrpy | GU | SXQOL | 0 | E | 65 | 24 | 4 | 0 | 0 | 0 | 09/24/2021 | 193 | 62 | ||
65 | 24 | 4 | 0 | 0 | 0 | ||||||||||
1 | E | 65 | 24 | 4 | 0 | 0 | 0 | ||||||||
65 | 24 | 4 | 0 | 0 | 0 | ||||||||||
EA8212-Blad, NMIBC, BRIDGE | GU | SXQOL | 1 | E | 252 | 125 | 68 | 37 | 10 | 4 | 02/07/2023 | 162 | 73 | ||
252 | 125 | 68 | 37 | 10 | 4 | ||||||||||
EAA173-MYEL, SMM, Rd +/- Daratumumab | MMYEL | SXQOL | 0 | E | 78 | 10 | 3 | 3 | 2 | 1 | 01/08/2020 | 252 | 100 | ||
78 | 10 | 3 | 3 | 2 | 1 | ||||||||||
1 | E | 38 | 6 | 1 | 1 | 1 | 1 | ||||||||
38 | 6 | 1 | 1 | 1 | 1 | ||||||||||
EAQ202-Improving AYA PROs in EA Trials | SXQOL | 1 | E | 43 | 0 | 0 | 0 | 0 | 0 | 12/13/2021 | 42 | 22 | |||
43 | 0 | 0 | 0 | 0 | 0 | ||||||||||
EAQ221CD-Breast, Metastatic, Imp. Adherence | CCD | 0 | E | 4 | 4 | 4 | 2 | 2 | 0 | 01/13/2025 | 141 | 49 | |||
4 | 4 | 4 | 2 | 2 | 0 | ||||||||||
1 | E | 3 | 3 | 3 | 1 | 1 | 0 | ||||||||
3 | 3 | 3 | 1 | 1 | 0 | ||||||||||
NRGBN003-Mening, Grd II, Observation vs Irradiation | OTHER | SXQOL | 1 | E | 5 | 0 | 0 | 0 | 0 | 0 | 06/24/2019 | 293 | 87 | ||
5 | 0 | 0 | 0 | 0 | 0 | ||||||||||
2 | E | 3 | 0 | 0 | 0 | 0 | 0 | ||||||||
3 | 0 | 0 | 0 | 0 | 0 | ||||||||||
NRGBN011-Brain, Lomustine + Temo vs Temo | OTHER | SXQOL | 1 | E | 38 | 19 | 7 | 1 | 0 | 0 | 07/18/2022 | 302 | 116 | ||
38 | 19 | 7 | 1 | 0 | 0 | ||||||||||
2 | E | 11 | 7 | 2 | 0 | 0 | 0 | ||||||||
11 | 7 | 2 | 0 | 0 | 0 | ||||||||||
NRGBN012-Brain, Pre- vs Post-Op Stereotactic Radiosurg | OTHER | SXQOL | 1 | E | 4 | 1 | 0 | 0 | 0 | 0 | 05/30/2023 | 225 | 89 | ||
4 | 1 | 0 | 0 | 0 | 0 | ||||||||||
NRGBR007-Breast, Stg I, De-Escalation of Breast RT | BREAST | SXQOL | 1 | E | 25 | 16 | 8 | 3 | 1 | 0 | 06/01/2022 | 402 | 177 | ||
25 | 16 | 8 | 3 | 1 | 0 | ||||||||||
2 | E | 23 | 14 | 7 | 3 | 1 | 0 | ||||||||
23 | 14 | 7 | 3 | 1 | 0 | ||||||||||
NRGBR008-Breast, LowRisk HER2+, Radiotherapy | BREAST | SXQOL | 1 | E | 1 | 1 | 1 | 0 | 0 | 0 | 03/10/2025 | 8 | 3 | ||
1 | 1 | 1 | 0 | 0 | 0 | ||||||||||
NRGBR009-Breast, EarlyStg, Adjuvant Chemo | BREAST | SXQOL | 1 | E | 15 | 12 | 7 | 4 | 1 | 0 | 01/31/2024 | 453 | 192 | ||
15 | 12 | 7 | 4 | 1 | 0 | ||||||||||
2 | E | 15 | 12 | 7 | 4 | 1 | 0 | ||||||||
15 | 12 | 7 | 4 | 1 | 0 | ||||||||||
NRGCC005-Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs | PREV | 1 | E | 77 | 67 | 41 | 22 | 6 | 1 | 12/05/2023 | 191 | 78 | |||
77 | 67 | 41 | 22 | 6 | 1 | ||||||||||
NRGCC008-Ovar, BRCA1, non-inferiority of BLS vs BSO | PREV | SXQOL | 1 | E | 12 | 3 | 1 | 1 | 0 | 0 | 04/08/2021 | 324 | 137 | ||
12 | 3 | 1 | 1 | 0 | 0 | ||||||||||
NRGGI006-Esophagus, Stg I-IVA, PBT vs IMRT | GI | SXQOL | 1 | E | 1 | 0 | 0 | 0 | 0 | 0 | 06/21/2024 | 89 | 34 | ||
1 | 0 | 0 | 0 | 0 | 0 | ||||||||||
2 | E | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
1 | 0 | 0 | 0 | 0 | 0 | ||||||||||
NRGGU009-Pros, PREDICT-RT | GU | SXQOL | 1 | E | 94 | 29 | 6 | 3 | 1 | 0 | 03/01/2022 | 466 | 171 | ||
94 | 29 | 6 | 3 | 1 | 0 | ||||||||||
2 | E | 87 | 29 | 6 | 3 | 2 | 0 | ||||||||
87 | 29 | 6 | 3 | 2 | 0 | ||||||||||
NRGGU010-Pros, Parallel De-Intens & Intens Trials | GU | SXQOL | 1 | E | 68 | 28 | 2 | 1 | 1 | 0 | 01/03/2022 | 451 | 164 | ||
68 | 28 | 2 | 1 | 1 | 0 | ||||||||||
2 | E | 63 | 27 | 2 | 1 | 1 | 0 | ||||||||
63 | 27 | 2 | 1 | 1 | 0 | ||||||||||
NRGGU013-Prostate, High-Risk, Five Fraction Radiation | GU | SXQOL | 1 | E | 9 | 7 | 4 | 3 | 1 | 0 | 05/28/2024 | 252 | 97 | ||
9 | 7 | 4 | 3 | 1 | 0 | ||||||||||
NRGGY026-Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE | OTHER | SXQOL | 1 | E | 2 | 1 | 1 | 1 | 1 | 0 | 05/28/2024 | 317 | 129 | ||
2 | 1 | 1 | 1 | 1 | 0 | ||||||||||
NRGHN006-HN, Erly Stg, Biopsy vs Dissection | OTHER | SXQOL | 1 | E | 3 | 1 | 0 | 0 | 0 | 0 | 08/06/2021 | 221 | 73 | ||
3 | 1 | 0 | 0 | 0 | 0 | ||||||||||
2 | E | 3 | 1 | 0 | 0 | 0 | 0 | ||||||||
3 | 1 | 0 | 0 | 0 | 0 | ||||||||||
NRGHN009-HN, RT + HD Cisp vs RT + LD Cisp for SCCHN | OTHER | SXQOL | 1 | E | 18 | 3 | 1 | 0 | 0 | 0 | 03/15/2022 | 280 | 104 | ||
18 | 3 | 1 | 0 | 0 | 0 | ||||||||||
R1216-HN, Adv,Cis vs Dtx vs Dtx+Cetux | OTHER | SXQOL | 1 | E | 7 | 1 | 0 | 0 | 0 | 0 | 07/24/2015 | 353 | 109 | ||
7 | 1 | 0 | 0 | 0 | 0 | ||||||||||
2 | E | 6 | 1 | 0 | 0 | 0 | 0 | ||||||||
6 | 1 | 0 | 0 | 0 | 0 | ||||||||||
Study | Admin | CCAdmin | Registration/Phase | Open Date |
---|---|---|---|---|
ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis | SXQOL | 2 Callback | 14-Aug-23 | |
AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | ERLYTX | SXQOL | 2 Late Randomization Callback | 08-May-17 |